Director of the Gamaleya Center Alexander Gintsburg said that clinical trials of a vaccine comprised of proteins from various COVID-19 strains might begin early 2022, TASS reports.
The development of a vaccine that protects against both the coronavirus and influenza is conceivable, but only after successful testing of a medication combining proteins from various coronavirus strains, according to Gintsburg.
If researchers are successful in linking many distinct tiny portions of coronavirus S-proteins, it will be feasible to utilize multiple flu virus hemagglutinins instead of coronavirus proteins. Gintsburg added that everything is conceivable.
